HOME >> MEDICINE >> NEWS
NIAID seeks applicants to lead revamped HIV/AIDS clinical trials networks

nue for up to seven years.

The research structure resulting from this competition will enable NIAID's Division of AIDS to more effectively respond to global research needs, including those of people of color, those who live in poverty, and women, all of whom are increasingly affected by the HIV/AIDS pandemic and continue to be under-represented in clinical research.

"We are pleased to be making this announcement on World AIDS Day," says Dr. Fauci, "as this year's World AIDS Day theme focuses on 'Women, Girls, HIV and AIDS'."

Each network leadership group selected as part of this competition will work with NIAID and other NIH Institutes on a focused research effort. To most effectively coordinate across disciplines, each network can address significant scientific questions in one or more of six priority research areas

  • Developing HIV vaccines
  • Translating research insights into therapeutic products to treat HIV disease
  • Optimizing clinical management of HIV/AIDS, including co-infections and other HIV-related conditions
  • Developing microbicides to prevent HIV acquisition and transmission
  • Preventing mother-to-child transmission of HIV
  • Developing other methods of HIV prevention

    The decision to revamp the clinical research structure emerged following extensive consultations with researchers, clinicians, community, nurses, advocates and people living with and at risk for HIV/AIDS. The new approach is designed to increase the efficiency, accountability and integration of NIAID's HIV/AIDS clinical research networks and enhance their capacity to effectively conduct vital clinical research, especially in resource-limited settings. Specifically, the new clinical research structure will

  • Maximize scientific opportunities by integrating and coordinating HIV/AIDS prevention, vaccine and therapeutic research and maintaining a flexible and responsive approach to emerg
    '"/>


  • Contact: NIAID Press Office
    niaidnews@niaid.nih.gov
    301-402-1663
    NIH/National Institute of Allergy and Infectious Diseases
    1-Dec-2004


    Page: 1 2 3

    Related medicine news :

    1. NIAID initiates trial of experimental avian flu vaccine
    2. NIAID seeks applicants to lead clinical trials units for revamped HIV/AIDS networks
    3. NIAID begins enrolling volunteers for novel HIV vaccine study
    4. NIAID-sponsored clinical trial aims to boost flu vaccine supply
    5. NIAID launches influenza genome sequencing project
    6. NIAID launches program to improve medical tools against emerging infectious diseases
    7. NIAID forms network to tackle potentially fatal reaction to smallpox vaccine
    8. NIAID rotavirus vaccine licensed for commercialization
    9. Second NIAID SARS vaccine candidate helps mice fend off SARS
    10. NIAID vaccine protects against SARS virus infection in mice
    11. NIAID Ebola vaccine enters human trial

    Post Your Comments:
    (Date:4/25/2015)... 25, 2015 On Friday, April 17, ... Journal’s annual Best Implementation Award. This award is ... best use of RFID technology to improve its manufacturing, ... company that best demonstrates how RFID is delivering real ... RFID Journal Live! 2015 in San Diego, the RFID ...
    (Date:4/24/2015)... As the nation recognizes the Month ... of these young men and women, the “Alaska – ... their Families” presents a special training session on Adverse ... a better understanding of the effect of childhood trauma ... – civilian and military – who provide services and ...
    (Date:4/24/2015)... The 1975 have had an intense ... globe to theaters, festivals and TV performances. Now that they’ve ... their label, Dirty Hit Records, to provide clean drinking water ... launched Cadence & Cause website, this four-piece has ... and a signed photo card. Entries from this sweepstakes ...
    (Date:4/24/2015)... Versailles, KY (PRWEB) April 24, 2015 ... Planning for Medical Field Professionals, today announced their exclusive ... their national Long Term Care Insurance distribution partner. , ... the Long Term Care Insurance benefits for associations, and ... Association for its Long Term Care Insurance member ...
    (Date:4/24/2015)... Insuranceautoquote.info has released a new blog post ... , Lowering auto insurance prices is not difficult. ... better offers for their financial budget. Comparing prices by ... require any registration. , Comparing quotes can help ... agencies that sell coverage and this means that clients ...
    Breaking Medicine News(10 mins):Health News:Seeonic’s Industry Leading Technology Powers Interstate Batteries to Winning Award 2Health News:Coalition Presents Resiliency Training to Raise Awareness during Month of the Military Child (#MOTMC2015) 2Health News:Internationally Recognized British Indie Rock Outfit The 1975 Partner with Cadence & Cause to Provide Clean Drinking Water to Those in Need 2Health News:Car Insurance Quotes Can Help Drivers Lower Their Premiums 2
    (Date:4/23/2015)... NORTH CHICAGO, Ill. , April 24, 2015 /PRNewswire/ ... U.S. Food and Drug Administration (FDA) has accepted its ... the company,s, all-oral, interferon-free, two direct-acting antiviral treatment of ... is for the treatment of adults with chronic genotype ... AbbVie,s regimen is the first all-oral, interferon-free therapy being ...
    (Date:4/23/2015)... 2015 /CNW/ - Health Canada is working with the ... the safety information regarding the risk of serious cardiovascular ... products are used at high doses (at or above ... of use. Ibuprofen is a non-steroidal anti-inflammatory ... to reduce inflammation. The majority of ibuprofen products in ...
    (Date:4/23/2015)... , Apr. 23, 2015 Surna, Inc. ... and distributes state-of-the art equipment and systems for ... commercial indoor cannabis cultivation, will host a shareholder ... April 27, 2015, at 4:15 PM Eastern Standard ... The conference call will be listen-in only, but ...
    Breaking Medicine Technology:U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 3U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 4U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 5U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 6U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 7Information Update - New safety information for prescription-strength ibuprofen: Risk of heart attack and stroke at high doses 2Information Update - New safety information for prescription-strength ibuprofen: Risk of heart attack and stroke at high doses 3Information Update - New safety information for prescription-strength ibuprofen: Risk of heart attack and stroke at high doses 4Surna, Inc. Announces Shareholder Conference Call 2Surna, Inc. Announces Shareholder Conference Call 3
    Cached News: